×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Forte Biosciences Inc. (FBRX) NASDAQ

$0.72 (0.01) (-1.37%)

Market Cap: $26.32M

As of 04/11/24 04:00 PM EDT. Market closed.

(FBRX)

Forte Biosciences Inc. (FBRX)
NASDAQ

$0.72
(0.01) (-1.37%)

Market Cap: $26.32M

As of 04/11/24 04:00 PM EDT. Market closed.

Add to Portfolio

we are driven by a vision to end cancer mortality. our company was founded on this vision in 2007. tocagen’s mission is to become a leading biopharmaceutical company for the treatment of cancer using cancer-selective gene therapy products based on our retroviral gene therapy platforms to increase lifespan, initially for patients with advanced local and metastatic cancer. our broadly applicable ... read more

we are driven by a vision to end cancer mortality. our company was founded on this vision in 2007. tocagen’s mission is to become a leading biopharmaceutical company for the treatment of cancer using cancer-selective gene therapy products based on our retroviral gene therapy platforms to increase lifespan, initially for patients with advanced local and metastatic cancer. our broadly applicable product candidates are designed to activate a patient’s immune system against their cancer from within. at the core of our approach is a novel gene therapy platform that utilizes retroviral replicating vectors (rrvs), which are designed to selectively deliver therapeutic genes into the dna of cancer cells. our proprietary platform is designed to fight cancer through a combination of mechanisms of action without the autoimmune toxicities that patients commonly experience with other treatments. in other words, our technology is designed to combat cancer with fewer side effects, keeping patients’ he read less

COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Martin Duvall
Full Time Employees
19
URL
Address
1124 W Carson Street, Mrl Building 3-320, California, Torrance, 90502.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Martin Duvall
Full Time Employees
19
Address
1124 W Carson Street, Mrl Building 3-320, California, Torrance, 90502.
PRICE CHART FOR FORTE BIOSCIENCES INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
-
Previous Close
$0.73
Days Range
$0.70 - $0.72
52 week range
$0.38 - $1.15
Volume
22,179
Avg. Volume (30 days)
26,186
Market Cap
$26.32M
Dividend Yield
-
P/E
(0.43)
Shares Outstanding
36,394,882
Open
-
Previous Close
$0.73
Days Range
$0.70 - $0.72
52 week range
$0.38 - $1.15
Volume
22,179
Avg. Volume (30 days)
26,186
Market Cap
$26.32M
Dividend Yield
-
P/E
(0.43)
Shares Outstanding
36,394,882
FINANCIAL STATEMENTS FOR FORTE BIOSCIENCES INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR FORTE BIOSCIENCES INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Riley Antony ACHIEF FINANCIAL OFFICERApr 01, 2024 Option Exercise$0.713,3452,367194,474Apr 02, 2024, 06:32 PM
Wagner Paul A.SEE REMARKSApr 01, 2024 Option Exercise$0.712,4531,7351,879,174Apr 02, 2024, 06:31 PM
Chen Hubert CSee remarksJan 01, 2024 Option Exercise$0.823,0732,52593,405Jan 03, 2024, 04:04 PM
Riley Antony AChief Financial OfficerJan 01, 2024 Option Exercise$0.823,8413,156188,444Jan 03, 2024, 04:02 PM
Wagner Paul A.See RemarksDec 18, 2023 Buy$0.7510,0007,5251,823,236Dec 20, 2023, 10:56 AM
Wagner Paul A.See RemarksDec 14, 2023 Buy$0.7210,0007,2001,813,236Dec 15, 2023, 06:29 PM
Wagner Paul A.See RemarksDec 13, 2023 Buy$0.7010,5207,3511,803,236Dec 15, 2023, 06:29 PM
Wagner Paul A.See RemarksDec 11, 2023 Buy$0.6525,00016,1871,787,940Dec 12, 2023, 07:30 PM
Wagner Paul A.See RemarksDec 12, 2023 Buy$0.654,7763,0881,792,716Dec 12, 2023, 07:30 PM
Wagner Paul A.See RemarksDec 08, 2023 Buy$0.6215,0009,3001,762,940Dec 08, 2023, 07:20 PM
Wagner Paul A.See RemarksDec 07, 2023 Buy$0.5836,20321,1681,747,940Dec 08, 2023, 07:20 PM
Wagner Paul A.See RemarksNov 22, 2023 Buy$0.434001721,711,737Nov 22, 2023, 05:51 PM
Wagner Paul A.See RemarksNov 20, 2023 Buy$0.446,9663,0481,711,337Nov 22, 2023, 05:51 PM
Chen Hubert CSee remarksOct 01, 2023 Option Exercise$0.662,5931,71788,978Oct 03, 2023, 04:29 PM
Wagner Paul A.See RemarksOct 01, 2023 Option Exercise$0.662,4531,6241,704,371Oct 03, 2023, 04:26 PM
Kornfeld StevenDirectorJul 31, 2023 Option Exercise$1.0199,00999,99999,009Aug 02, 2023, 06:03 PM
Williams Donald AllenDirectorJul 31, 2023 Option Exercise$1.0159,40559,99959,405Aug 02, 2023, 06:02 PM
GRYSKA DAVID WDirectorJul 31, 2023 Option Exercise$1.01148,514149,999148,514Aug 02, 2023, 06:00 PM
Chen Hubert CSee remarksJul 31, 2023 Option Exercise$1.0174,25775,00084,071Aug 02, 2023, 05:58 PM
Riley Antony AChief Financial OfficerJul 31, 2023 Option Exercise$1.01148,514149,999176,776Aug 02, 2023, 05:57 PM
Wagner Paul A.See RemarksJul 31, 2023 Option Exercise$1.01247,524249,9991,675,574Aug 02, 2023, 05:56 PM
Riley Antony AChief Financial OfficerJul 01, 2023 Option Exercise$1.043,2413,37124,762Jul 05, 2023, 04:06 PM
Wagner Paul A.See RemarksJul 01, 2023 Option Exercise$1.042,4532,5511,428,050Jul 05, 2023, 04:04 PM
Wagner Paul A.See RemarksApr 01, 2023 Option Exercise$1.0111,04611,1561,399,253Apr 04, 2023, 08:19 PM
Riley Antony AChief Financial OfficerApr 01, 2023 Option Exercise$1.013,2413,27318,628Apr 04, 2023, 08:18 PM
Chen Hubert CSee remarksApr 01, 2023 Option Exercise$1.012,5932,6194,907Apr 04, 2023, 08:17 PM
Wagner Paul A.See RemarksDec 15, 2022 Buy$1.0355,97657,6721,335,025Dec 19, 2022, 04:21 PM
Wagner Paul A.See RemarksDec 16, 2022 Buy$1.0744,02447,0001,379,049Dec 19, 2022, 04:21 PM
Wagner Paul A.See RemarksSep 07, 2021 Sale$4.351,000,0004,347,1001,279,049Sep 08, 2021, 05:02 PM
Riley Antony AChief Financial OfficerSep 07, 2021 Sale$4.2425,000106,10514,581Sep 07, 2021, 04:09 PM
DARCY THOMAS EDirectorJan 13, 2021 Option Exercise$9.595004,7932,358Jan 14, 2021, 07:17 PM
Riley Antony AChief Financial OfficerJun 29, 2020 Buy$14.112,00028,22036,065Jun 30, 2020, 08:07 PM
Riley Antony AChief Financial OfficerJun 26, 2020 Buy$14.524,70068,22534,065Jun 30, 2020, 08:07 PM
Wagner Paul A.See RemarksJun 25, 2020 Buy$14.487,000101,3562,279,049Jun 29, 2020, 08:13 PM
Oliveira Steven Michael10% OwnerApr 14, 2020 Buy$1.1974,30188,4182,873,450Apr 14, 2020, 05:00 PM
Oliveira Steven Michael10% OwnerMar 02, 2020 Buy$1.3565,14987,7562,799,149Mar 03, 2020, 04:17 PM
Hasnain FaheemDirectorMay 30, 2019 Buy$4.6643,000200,315245,857Jun 03, 2019, 04:11 PM
Jolly DouglasEVP, Research & Pharm DevelDec 10, 2018 Option Exercise$8.197325,995393,478May 29, 2019, 04:32 PM
Jolly DouglasEVP, Research & Pharm DevelJun 08, 2018 Option Exercise$8.197035,758392,746May 29, 2019, 04:32 PM
FOLETTA MARK GEVP & Chief Financial OfficerMay 28, 2019 Buy$4.305,00021,47515,042May 29, 2019, 04:29 PM
Duvall Martin JChief Executive OfficerMay 28, 2019 Buy$4.345,00021,67913,605May 29, 2019, 04:25 PM
GRUBER HARRY EPresident, Science&InnovationMay 24, 2019 Buy$4.565,00022,7829,744May 29, 2019, 04:22 PM
Das AshaSVP & Chief Medical OfficerDec 08, 2017 Option Exercise$8.502,50021,2505,000Dec 14, 2017, 09:10 PM
FOLETTA MARK GEVP & Chief Financial OfficerDec 08, 2017 Option Exercise$8.502,50021,2507,500Dec 14, 2017, 09:07 PM
Duvall Martin JChief Executive OfficerDec 08, 2017 Option Exercise$8.502,50021,2506,071Dec 14, 2017, 09:02 PM
GRUBER HARRY EPresident, Research & DevelDec 08, 2017 Option Exercise$8.502,50021,2502,500Dec 14, 2017, 08:51 PM
Jolly DouglasEVP, Research & Pharm DevelDec 08, 2017 Option Exercise$8.507396,282392,043Dec 14, 2017, 08:46 PM
Das AshaSVP & Chief Medical OfficerApr 19, 2017 Buy$10.002,50025,0002,500Apr 21, 2017, 05:44 PM
FOLETTA MARK GEVP & Chief Financial OfficerApr 19, 2017 Buy$10.005,00050,0005,000Apr 21, 2017, 05:42 PM
GRUBER HARRY EPresident, Research & DevelApr 19, 2017 Buy$10.0025,000250,000417,753Apr 21, 2017, 05:41 PM
Duvall Martin JChief Executive OfficerApr 19, 2017 Option Exercise$10.003,57135,7103,571Apr 21, 2017, 05:39 PM
BERGER FRANKLIN MDirectorApr 19, 2017 Option Exercise$10.0025,335253,35025,335Apr 21, 2017, 05:37 PM
SCHIMMEL PAULDirectorApr 19, 2017 Buy$10.0010,000100,00013,623Apr 21, 2017, 05:34 PM
Hasnain FaheemDirectorApr 19, 2017 Option Exercise$10.00102,8571,028,570102,857Apr 21, 2017, 05:28 PM
Hasnain FaheemDirectorApr 19, 2017 Buy$10.00100,0001,000,000202,857Apr 21, 2017, 05:28 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Riley Antony ACHIEF FINANCIAL OFFICER04/01/20242,367
Wagner Paul A.SEE REMARKS04/01/20241,735
Chen Hubert CSee remarks01/01/20242,525
Riley Antony AChief Financial Officer01/01/20243,156
Wagner Paul A.See Remarks12/18/20237,525
Wagner Paul A.See Remarks12/14/20237,200
Wagner Paul A.See Remarks12/13/20237,351
Wagner Paul A.See Remarks12/11/202316,187
Wagner Paul A.See Remarks12/12/20233,088
Wagner Paul A.See Remarks12/08/20239,300
Wagner Paul A.See Remarks12/07/202321,168
Wagner Paul A.See Remarks11/22/2023172
Wagner Paul A.See Remarks11/20/20233,048
Chen Hubert CSee remarks10/01/20231,717
Wagner Paul A.See Remarks10/01/20231,624
Kornfeld StevenDirector07/31/202399,999
Williams Donald AllenDirector07/31/202359,999
GRYSKA DAVID WDirector07/31/2023149,999
Chen Hubert CSee remarks07/31/202375,000
Riley Antony AChief Financial Officer07/31/2023149,999
Wagner Paul A.See Remarks07/31/2023249,999
Riley Antony AChief Financial Officer07/01/20233,371
Wagner Paul A.See Remarks07/01/20232,551
Wagner Paul A.See Remarks04/01/202311,156
Riley Antony AChief Financial Officer04/01/20233,273
Chen Hubert CSee remarks04/01/20232,619
Wagner Paul A.See Remarks12/15/202257,672
Wagner Paul A.See Remarks12/16/202247,000
Wagner Paul A.See Remarks09/07/20214,347,100
Riley Antony AChief Financial Officer09/07/2021106,105
DARCY THOMAS EDirector01/13/20214,793
Riley Antony AChief Financial Officer06/29/202028,220
Riley Antony AChief Financial Officer06/26/202068,225
Wagner Paul A.See Remarks06/25/2020101,356
Oliveira Steven Michael10% Owner04/14/202088,418
Oliveira Steven Michael10% Owner03/02/202087,756
Hasnain FaheemDirector05/30/2019200,315
Jolly DouglasEVP, Research & Pharm Devel12/10/20185,995
Jolly DouglasEVP, Research & Pharm Devel06/08/20185,758
FOLETTA MARK GEVP & Chief Financial Officer05/28/201921,475
Duvall Martin JChief Executive Officer05/28/201921,679
GRUBER HARRY EPresident, Science&Innovation05/24/201922,782
Das AshaSVP & Chief Medical Officer12/08/201721,250
FOLETTA MARK GEVP & Chief Financial Officer12/08/201721,250
Duvall Martin JChief Executive Officer12/08/201721,250
GRUBER HARRY EPresident, Research & Devel12/08/201721,250
Jolly DouglasEVP, Research & Pharm Devel12/08/20176,282
Das AshaSVP & Chief Medical Officer04/19/201725,000
FOLETTA MARK GEVP & Chief Financial Officer04/19/201750,000
GRUBER HARRY EPresident, Research & Devel04/19/2017250,000
Duvall Martin JChief Executive Officer04/19/201735,710
BERGER FRANKLIN MDirector04/19/2017253,350
SCHIMMEL PAULDirector04/19/2017100,000
Hasnain FaheemDirector04/19/20171,028,570
Hasnain FaheemDirector04/19/20171,000,000
Load More Insider Transactions
FUNDS WITH A POSITION IN FORTE BIOSCIENCES INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
TYBOURNE CAPITAL MANAGEMENT (HK) LTD3,624,5480.44%No changeGrowth, Growth At A Reasonable Price
FARALLON CAPITAL MANAGEMENT LLC1,810,4550.00738%No changeEvent Driven, Value
GEODE CAPITAL MANAGEMENT, LLC336,6050.00003%61.53%Other
BLACKROCK INC.182,3240%0.09%Other
RENAISSANCE TECHNOLOGIES LLC129,8000.00017%2.29%Other
CHANGE IN SHARES OUTSTANDING FOR FORTE BIOSCIENCES INC
STOCK BUYBACKS FOR FORTE BIOSCIENCES INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2023
09/30/2023
-16.62%
1Q
12/31/2023
09/30/2022
66.80%
5Q

Period of Report: 12/31/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2023
-16.62%
1Q
09/30/2022
66.80%
5Q
BUYBACK ANNOUNCEMENT(S) FOR FORTE BIOSCIENCES INC
LOADING...